Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis

Area of Science:

• Neuroimmunology
• Autoimmunity
• Central Nervous System (CNS) Disorders

Background:

• Multiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the CNS.
• B cells play a central role in MS immunopathology, as evidenced by successful B-cell-depleting therapies.
• However, the specific target antigens of the pathogenic B-cell response in MS remain largely unknown.

Purpose of the Study:

• To identify novel target antigens of the autoimmune response in multiple sclerosis (MS).
• To investigate the role of identified antigens in the pathogenesis of MS and other neuroinflammatory diseases.

Main Methods:

• Combined polyclonal B-cell stimulation with human proteome-wide protein microarrays to screen for MS-specific autoantibodies.
• Validated findings using enzyme-linked immunosorbent assay (ELISA) in independent patient cohorts and cerebrospinal fluid (CSF).
• Utilized experimental autoimmune encephalomyelitis (EAE) mouse model to assess the pathogenicity of identified autoantibodies.

Main Results:

• A significantly elevated antibody response against the membrane protein modulator of VRAC current 1 (MLC1) was detected in MS patients' B-cell supernatants and serum.
• Elevated MLC1 antibody titers were also observed in the CSF of patients with neuroinflammatory diseases other than MS.
• In the EAE model, anti-MLC1 antibodies bound to cerebral cortical neurons and led to mortality in a subset of mice.

Conclusions:

• The study identified MLC1 as a potential autoantigen in MS and other neuroinflammatory disorders.
• MLC1 is expressed in neurons and astrocytes, suggesting a direct role in CNS autoimmunity.
• Further research is warranted to explore the diagnostic and prognostic value of MLC1-specific antibodies in neuroinflammatory conditions.